Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intralesional interferon therapy for basal cell carcinoma.

R C Cornell1, H T Greenway, S B Tucker

  • 1Division of Dermatology and Cutaneous Surgery, Scripps Clinic and Research Foundation, La Jolla, CA 92037.

Journal of the American Academy of Dermatology
|October 1, 1990
PubMed
Summary

Intralesional interferon alfa-2b effectively treated basal cell carcinomas, achieving an 86% cure rate. This treatment offers a promising alternative for patients with noduloulcerative or superficial basal cell carcinomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anaesthetic management of abdominal trauma.

BJA education·2025
Same author

Factors that influence the quality of the clinical supervision experience in a first contact physiotherapy (FCP) role - The perspectives of supervisors and supervisees - A qualitative analysis.

Musculoskeletal science & practice·2024
Same author

Management of acute cervical spinal cord injury in the non-specialist intensive care unit: a narrative review of current evidence.

Anaesthesia·2023
Same author

Chondrocytic and pharmacokinetic properties of Phlpp inhibitors.

Osteoarthritis and cartilage open·2022
Same author

Bi-national outbreak of <i>Salmonella</i> Newport infections linked to onions: the United States experience.

Epidemiology and infection·2022
Same author

Point-of-care lung ultrasound in the assessment of suspected COVID-19: a retrospective service evaluation with a severity score.

Acute medicine·2020

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Basal cell carcinoma (BCC) is the most common type of skin cancer.
  • Current treatments for BCC include surgery, radiation, and topical therapies.
  • Novel therapeutic approaches are needed for effective BCC management.

Purpose of the Study:

  • To evaluate the efficacy and safety of intralesional interferon alfa-2b for treating noduloulcerative and superficial basal cell carcinomas.

Main Methods:

  • A randomized clinical trial involving 172 patients across four medical centers.
  • Patients received intralesional interferon alfa-2b (1.5 x 10^6 IU) or placebo three times weekly for 3 weeks.
  • Treatment efficacy was assessed via biopsy at 16-20 weeks and tumor-free status at 1 year.

Related Experiment Videos

Main Results:

  • A significantly higher cure rate was observed in the interferon group (86%) compared to placebo (29%) at 16-20 weeks.
  • Tumor-free rates at 1 year were 81% for interferon recipients versus 20% for placebo recipients.
  • Mild, transient flu-like symptoms were the most common side effects, with only three patients discontinuing treatment.

Conclusions:

  • Intralesional interferon alfa-2b demonstrates significant efficacy and a favorable safety profile for treating superficial and noduloulcerative basal cell carcinomas.
  • This therapeutic option may be suitable for patients with specific types of basal cell carcinoma.
  • Further research could explore interferon alfa-2b in combination therapies or for other skin malignancies.